Compare NWE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | CRNX |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 2023 | 2018 |
| Metric | NWE | CRNX |
|---|---|---|
| Price | $72.13 | $83.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $66.50 | ★ $76.75 |
| AVG Volume (30 Days) | 421.0K | ★ 6.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,610,559,000.00 | $1,039,000.00 |
| Revenue This Year | $8.84 | $720.10 |
| Revenue Next Year | $5.31 | $184.67 |
| P/E Ratio | $71.18 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $51.99 | $25.83 |
| 52 Week High | $75.18 | $84.00 |
| Indicator | NWE | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 92.91 |
| Support Level | $69.08 | $41.42 |
| Resistance Level | $74.24 | N/A |
| Average True Range (ATR) | 1.54 | 0.85 |
| MACD | 0.12 | 2.82 |
| Stochastic Oscillator | 55.16 | 99.68 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.